Iovance Total Current Assets vs Net Tangible Assets Analysis

IOVA Stock

USD 3.54 0.29 8.92%

Iovance Biotherapeutics financial indicator trend analysis is infinitely more than just investigating Iovance Biotherapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iovance Biotherapeutics is a good investment. Please check the relationship between Iovance Biotherapeutics Total Current Assets and its Net Tangible Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

Total Current Assets vs Net Tangible Assets

Total Current Assets vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iovance Biotherapeutics Total Current Assets account and Net Tangible Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Iovance Biotherapeutics' Total Current Assets and Net Tangible Assets is 0.92. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Iovance Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Iovance Biotherapeutics' Total Current Assets and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Iovance Biotherapeutics are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Total Current Assets i.e., Iovance Biotherapeutics' Total Current Assets and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.92

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Iovance Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iovance Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.At present, Iovance Biotherapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 441.6 M, whereas Tax Provision is projected to grow to (2.7 M).

	2022	2023	2024	2025 (projected)
Net Interest Income	3.0M	11.6M	20.3M	21.3M
Interest Income	3.0M	11.6M	20.3M	21.3M

Net Interest Income Interest Income

Iovance Biotherapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Intangible Assets	Accounts Payable	Non Currrent Assets Other	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Other Assets	Retained Earnings Total Equity
Total Assets		0.91	0.93	0.99	0.92	-0.1	-0.92	0.43	0.82	0.79	0.75	0.95	0.91	0.96	0.93	0.92	0.83	0.88	0.94	0.9	-0.05	0.85	0.98	-0.41	0.63	-0.95
Other Current Liab	0.91		0.98	0.88	0.92	-0.01	-0.98	0.33	0.95	0.5	0.66	0.96	0.83	0.98	0.97	0.94	0.56	0.97	0.82	0.93	0.05	0.8	0.81	-0.28	0.62	-0.89
Total Current Liabilities	0.93	0.98		0.88	0.96	0.0	-0.98	0.37	0.89	0.56	0.71	0.95	0.84	0.98	0.99	0.98	0.61	0.95	0.85	0.97	-0.09	0.87	0.83	-0.31	0.65	-0.94
Total Stockholder Equity	0.99	0.88	0.88		0.88	-0.12	-0.88	0.43	0.78	0.83	0.75	0.93	0.91	0.93	0.89	0.88	0.87	0.84	0.95	0.86	-0.03	0.82	0.99	-0.43	0.61	-0.93
Property Plant And Equipment Net	0.92	0.92	0.96	0.88		-0.05	-0.93	0.46	0.81	0.66	0.73	0.88	0.8	0.93	0.98	1.0	0.68	0.87	0.81	0.96	-0.19	0.96	0.85	-0.3	0.72	-0.97
Net Debt	-0.1	-0.01	0.0	-0.12	-0.05		0.11	-0.88	0.11	-0.13	0.17	-0.15	-0.04	-0.11	-0.02	-0.06	-0.16	0.02	0.02	0.01	0.42	-0.13	-0.13	0.36	0.12	0.09
Retained Earnings	-0.92	-0.98	-0.98	-0.88	-0.93	0.11		-0.43	-0.9	-0.52	-0.68	-0.97	-0.85	-0.99	-0.98	-0.96	-0.6	-0.96	-0.84	-0.94	0.08	-0.84	-0.82	0.33	-0.55	0.91
Cash	0.43	0.33	0.37	0.43	0.46	-0.88	-0.43		0.16	0.42	0.21	0.42	0.33	0.43	0.4	0.45	0.46	0.27	0.28	0.38	-0.51	0.56	0.44	-0.46	0.2	-0.49
Non Current Assets Total	0.82	0.95	0.89	0.78	0.81	0.11	-0.9	0.16		0.35	0.55	0.89	0.8	0.89	0.88	0.84	0.42	0.91	0.7	0.84	0.34	0.67	0.7	-0.24	0.56	-0.76
Cash And Short Term Investments	0.79	0.5	0.56	0.83	0.66	-0.13	-0.52	0.42	0.35		0.71	0.59	0.69	0.6	0.6	0.61	0.98	0.44	0.81	0.62	-0.2	0.71	0.9	-0.44	0.59	-0.78
Common Stock Total Equity	0.75	0.66	0.71	0.75	0.73	0.17	-0.68	0.21	0.55	0.71		0.65	0.73	0.69	0.72	0.71	0.76	0.72	0.79	0.73	-0.13	0.73	0.75	-0.05	0.52	-0.79
Common Stock Shares Outstanding	0.95	0.96	0.95	0.93	0.88	-0.15	-0.97	0.42	0.89	0.59	0.65		0.9	0.99	0.93	0.9	0.66	0.94	0.89	0.91	0.02	0.76	0.87	-0.4	0.51	-0.89
Other Current Assets	0.91	0.83	0.84	0.91	0.8	-0.04	-0.85	0.33	0.8	0.69	0.73	0.9		0.88	0.84	0.8	0.75	0.82	0.89	0.84	0.16	0.74	0.88	-0.39	0.39	-0.87
Other Stockholder Equity	0.96	0.98	0.98	0.93	0.93	-0.11	-0.99	0.43	0.89	0.6	0.69	0.99	0.88		0.97	0.95	0.67	0.96	0.89	0.94	-0.06	0.84	0.88	-0.36	0.57	-0.93
Total Liab	0.93	0.97	0.99	0.89	0.98	-0.02	-0.98	0.4	0.88	0.6	0.72	0.93	0.84	0.97		0.99	0.64	0.93	0.84	0.97	-0.11	0.91	0.85	-0.3	0.66	-0.95
Property Plant And Equipment Gross	0.92	0.94	0.98	0.88	1.0	-0.06	-0.96	0.45	0.84	0.61	0.71	0.9	0.8	0.95	0.99		0.65	0.9	0.81	0.96	-0.17	0.94	0.84	-0.3	0.69	-0.96
Total Current Assets	0.83	0.56	0.61	0.87	0.68	-0.16	-0.6	0.46	0.42	0.98	0.76	0.66	0.75	0.67	0.64	0.65		0.51	0.84	0.65	-0.18	0.73	0.92	-0.44	0.52	-0.8
Common Stock	0.88	0.97	0.95	0.84	0.87	0.02	-0.96	0.27	0.91	0.44	0.72	0.94	0.82	0.96	0.93	0.9	0.51		0.82	0.88	0.01	0.73	0.76	-0.17	0.49	-0.83
Intangible Assets	0.94	0.82	0.85	0.95	0.81	0.02	-0.84	0.28	0.7	0.81	0.79	0.89	0.89	0.89	0.84	0.81	0.84	0.82		0.86	-0.09	0.75	0.94	-0.37	0.54	-0.9
Accounts Payable	0.9	0.93	0.97	0.86	0.96	0.01	-0.94	0.38	0.84	0.62	0.73	0.91	0.84	0.94	0.97	0.96	0.65	0.88	0.86		-0.11	0.91	0.83	-0.35	0.69	-0.97
Non Currrent Assets Other	-0.05	0.05	-0.09	-0.03	-0.19	0.42	0.08	-0.51	0.34	-0.2	-0.13	0.02	0.16	-0.06	-0.11	-0.17	-0.18	0.01	-0.09	-0.11		-0.29	-0.07	0.02	-0.03	0.18
Short Long Term Debt Total	0.85	0.8	0.87	0.82	0.96	-0.13	-0.84	0.56	0.67	0.71	0.73	0.76	0.74	0.84	0.91	0.94	0.73	0.73	0.75	0.91	-0.29		0.82	-0.33	0.71	-0.95
Net Tangible Assets	0.98	0.81	0.83	0.99	0.85	-0.13	-0.82	0.44	0.7	0.9	0.75	0.87	0.88	0.88	0.85	0.84	0.92	0.76	0.94	0.83	-0.07	0.82		-0.46	0.63	-0.92
Current Deferred Revenue	-0.41	-0.28	-0.31	-0.43	-0.3	0.36	0.33	-0.46	-0.24	-0.44	-0.05	-0.4	-0.39	-0.36	-0.3	-0.3	-0.44	-0.17	-0.37	-0.35	0.02	-0.33	-0.46		-0.2	0.39
Other Assets	0.63	0.62	0.65	0.61	0.72	0.12	-0.55	0.2	0.56	0.59	0.52	0.51	0.39	0.57	0.66	0.69	0.52	0.49	0.54	0.69	-0.03	0.71	0.63	-0.2		-0.71
Retained Earnings Total Equity	-0.95	-0.89	-0.94	-0.93	-0.97	0.09	0.91	-0.49	-0.76	-0.78	-0.79	-0.89	-0.87	-0.93	-0.95	-0.96	-0.8	-0.83	-0.9	-0.97	0.18	-0.95	-0.92	0.39	-0.71

Click cells to compare fundamentals

Iovance Biotherapeutics Account Relationship Matchups

Iovance Biotherapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	768.5M	777.3M	664.0M	780.4M	910.4M	955.9M
Other Current Liab	28.8M	51.7M	39.7M	69.4M	81.9M	86.0M
Total Current Liabilities	54.9M	89.2M	91.5M	110.3M	122.3M	128.5M
Total Stockholder Equity	656.5M	621.7M	499.6M	584.6M	710.4M	745.9M
Property Plant And Equipment Net	113.9M	169.9M	178.2M	176.5M	164.3M	172.5M
Net Debt	(15.7M)	(6.7M)	(147.3M)	(39.0M)	(58.4M)	(61.4M)
Retained Earnings	(830.2M)	(1.2B)	(1.6B)	(2.0B)	(2.4B)	(2.3B)
Cash	67.3M	78.2M	231.7M	114.9M	115.7M	76.7M
Non Current Assets Total	132.4M	269.4M	6.4M	472.5M	453.4M	476.1M
Cash And Short Term Investments	629.4M	596.0M	471.8M	279.9M	323.8M	244.6M
Common Stock Shares Outstanding	138.3M	153.4M	159.3M	235.1M	289.9M	304.4M
Liabilities And Stockholders Equity	768.5M	777.3M	664.0M	780.4M	910.4M	955.9M
Other Current Assets	13.3M	7.1M	7.3M	17.5M	12.4M	13.0M
Other Stockholder Equity	1.5B	1.8B	2.1B	2.6B	3.1B	3.3B
Total Liab	112.0M	155.7M	164.3M	195.7M	200.0M	210.0M
Property Plant And Equipment Gross	113.9M	178.6M	195.0M	204.5M	200.3M	210.3M
Total Current Assets	636.1M	508.0M	471.8M	307.8M	457.0M	235.4M
Common Stock	6K	7K	8K	11K	13K	13.7K
Accounts Payable	13.5M	27.4M	26.6M	33.1M	27.5M	28.9M
Non Currrent Assets Other	12.9M	7.9M	(178.2M)	66.7M	6.7M	7.1M
Short Long Term Debt Total	51.7M	71.5M	84.4M	75.9M	57.3M	45.2M
Net Tangible Assets	299.0M	656.5M	621.7M	499.6M	574.6M	603.3M
Other Assets	8.9M	73.2M	777.3M	185.7M	213.6M	224.2M
Retained Earnings Total Equity	(372.8M)	(570.6M)	(830.2M)	(1.2B)	(1.1B)	(1.0B)
Short Term Investments	562.1M	426.2M	240.1M	165.0M	208.1M	191.0M
Capital Surpluse	839.0M	869.4M	1.5B	1.8B	2.1B	2.2B
Accumulated Other Comprehensive Income	19K	(601K)	(902K)	2.5M	(1.0M)	(993.7K)
Short Term Debt	12.6M	10.1M	25.2M	7.8M	12.9M	11.3M
Property Plant Equipment	8.5M	59.2M	100.9M	178.2M	205.0M	215.2M
Non Current Liabilities Total	57.1M	66.5M	84.4M	85.4M	77.7M	46.2M
Net Invested Capital	656.5M	622.7M	500.6M	585.6M	711.4M	548.3M
Net Working Capital	581.2M	418.8M	387.6M	197.5M	334.7M	384.7M
Capital Lease Obligations	51.7M	70.5M	84.4M	74.9M	57.3M	64.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:

How To Invest In Iovance

Details

Is Iovance Stock a good investment?

Details

What is Iovance Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.28)

Revenue Per Share

0.566

Quarterly Revenue Growth

151.892

Return On Assets

(0.29)

Return On Equity

(0.57)

The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

PTCT

PTC Therapeutics

48.37 -2.59 -5.08

MRTX

Mirati Ther

0.00 0.00 0.00

SRPT

Sarepta Therapeutics

62.47 0.56 0.90

CWBR

CohBar Inc

0.00 0.00 0.00

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iovance Total Current Assets vs Net Tangible Assets Analysis

Total Current Assets vs Net Tangible Assets

Total Current Assets vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Total Current Assets

Net Tangible Assets

Iovance Biotherapeutics fundamental ratios Correlations

Iovance Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iovance Biotherapeutics fundamental ratios Accounts

Also Currently Popular

Trending Assets

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Property Plant And Equipment Gross	+ 0.99	Total Liab

Other Stockholder Equity	- 0.99	Retained Earnings
Total Liab	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Retained Earnings	- 0.98	Other Current Liab
Retained Earnings Total Equity	- 0.97	Accounts Payable
Common Stock Shares Outstanding	- 0.97	Retained Earnings